Bolalarda Xodjkin limfomasini davolash samaradorligini 18F-FDG PET-KT tekshiruvi yordamida baholash: Klinik holat
Referat
Maqsad. Bolalarda Xodjkin limfomasini davolash samaradorligini kimyoterapiya kurslaridan keyin 18F-fluorodezoksiglyukoza (18F-FDG) bilan qo‘shib o‘tkazilgan pozitron-emission tomografiya va kompyuter tomografiyasi (PET/KT) yordamida klinik holat misolida baholash.
Material va usullar. Klinika holatini tahlil qilish usuli qo‘llanildi. Bolada Xodjkin limfomasini davolash samaradorligi PET/KT tekshiruvi yordamida baholandi. Bunda davolash boshlanishidan oldin kasallik bosqichini va zararlanish hajmini aniqlash uchun dastlabki PET/KT tekshiruvi o‘tkazildi, undan keyin kimyoterapiya kurslari va davolashga javobni baholash uchun qayta PET/KT o‘tkazildi. Natijalarni talqin qilishni standartlashtirish hamda o‘smalarning metabolik faolligini baholash uchun Deauville shkalasi qo‘llanildi.
Natijalar. 2024-yil 16-oktabrda o‘tkazilgan dastlabki PET/KT tekshiruvida Xodjkin limfomasining keng tarqalgan zararlanishi aniqlanib, u yuqori o‘mrov limfa tugunlarini, o‘rta ko‘krak qafasi bo‘shlig‘ini, qorin bo‘shlig‘ini hamda ikkala o‘pkani qamrab olgan. Ushbu holat Deauville shkalasi bo‘yicha 5 ball bilan baholandi, bu esa yuqori metabolik faollikka ishora qiladi. Kimyoterapiya kurslaridan keyin 2024-yil 18-dekabrda o‘tkazilgan nazorat PET/KT tekshiruvida to‘liq metabolik javob qayd etildi, chunki ilgari zararlangan sohalarda izotopning patologik to‘planishi kuzatilmadi; natija Deauville shkalasi bo‘yicha 1 ball bilan baholandi.
Xulosa. Ushbu klinik holat PET/KT tekshiruvi yordamida 18F-FDG qo‘llashning bolalarda Xodjkin limfomasini davolash samaradorligini baholashda yuqori axborot beruvchanlik va klinik ahamiyatga ega ekanligini ko‘rsatadi. Mazkur usul ushbu kasallikda davolashga javobni baholashda “oltin standart” hisoblanadi va to‘liq metabolik javobni o‘z vaqtida va aniq aniqlash imkonini beradi. Natijada, ortiqcha radioterapiyadan voz kechish va davolash rejimlarini o‘zgartirish orqali o‘sayotgan organizmga toksik yukni kamaytirish mumkin bo‘ladi, bu esa bemorning hayot sifatini va tuzalish imkoniyatlarini oshiradi. Shunday qilib, PET/KTni pediatrik onkologiyada keng joriy etish zamonaviy diagnostika standartlarining ustuvor yo‘nalishiga aylanishi kerak.
Kalit so'zlar:
Mualliflar haqida
Adabiyotlar ro'yxati
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059-68. https://doi.org/10.1200/JCO.2013.54.8800.
Barrington SF, Kluge R. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging. 2017;44(1):97-110. https://doi.org/10.1007/s00259-017-3690-8.
Furth C, Steffen IG, Amthauer H, Ruf J. The role of FDG-PET in children with lymphoma. Semin Nucl Med. 2013;43(5):305-11. https://doi.org/10.1053/j.semnuclmed.2013.04.003.
Kazakh Research Institute of Oncology and Radiology. Indicators of the oncology service of the Republic of Kazakhstan for 2023 (statistical and analytical materials). Astana: Ministry of Health of the Republic of Kazakhstan; 2024. p.161-87.
Bacchiani M, Salamone V, Massaro E, Sandulli A, Mariottini R, Cadenar A, Di Maida F, Pradere B, Mertens LS, Longoni M, et al. Assessing the performance of 18F-FDG PET/CT in bladder cancer: A narrative review of current evidence. Diagnostics. 2023;13(12):1993. https://doi.org/10.3390/diagnostics13121993.
Filippi AR, Ricardi U. The role of FDG-PET in paediatric Hodgkin’s lymphoma: from initial staging to prognosis and response assessment. Pediatr Blood Cancer. 2015;62(10):1768-73. https://doi.org/10.1002/ pbc.25512.
Vali R, Alessio AM, Bar-Sever Z, et al. SNMMI and EANM practice guideline for pediatric 18F-FDG PET/CT. J Nucl Med. 2021;62(1):99-110. https://doi.org/10.2967/jnumed.120.246363.
Qanday qilib iqtibos keltirish mumkin
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.